PhaseBio Pharmaceuticals (PHAS.Q), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary disease, announced today that it has entered into an exclusive licensing…
Bio Tech
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and…
“Americans spend more on prescription drugs than anyone else in the world,” states Bloomberg, “It’s true that they take a lot of pills. But what really sets the U.S….
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth a combined $5.2 billion….